INTERCELL - No Tangible Value!
We recommend Intercell (ICLL)’s investors to remain on sideline, as there is no catalyst in 2011-12 that could boost the stock. Intercell (ICLL) woes of 2010 became worse in 2011 chiefly due to the failure of its late-stage vaccines in the pipeline and manufacturing problems of its marketed IXIARO JEV vaccine. With further management changes, cost cutting, there is little to cheer or feel optimistic about.
COMPANIES MENTIONED
INTERCELL, ICLL
INTERCELL, ICLL
More Publications
Value Grupo Financiero S.A. de C.V. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
US$ 499.00
September 2026
50 pages
